Is Karyopharm Therapeutics going out of business?

Karyopharm Therapeutics Inc. (KPTI) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Karyopharm Therapeutics Inc. (KPTI) scores 2 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 198.36% (YoY)

Five questions, kept separate

Survival - Critical

3-6 mo of estimated runway from 2026-06-30, based on $55.0M of cash and short-term investments against $146M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Poor

-56.2% operating margin and -99.4% FCF margin produce a poor Business Quality assessment.

Trajectory - Accelerating

Revenue, operating margin and cash margin improved together. Revenue improved 6.8%; operating margin improved 27.8pp; FCF margin improved 64.1pp. The TTM window includes a mixed-basis Q4 estimate.

Valuation - Extreme expectations

-379.1% FCF yield supports an extreme expectations Valuation assessment on the ttm basis.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; 2 adverse event families are active. It appears across 4 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 198.36% (YoY)
• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• Filing event risk: Going-Concern Warning, Clinical Trial Failure (-8 pts)
• Cash Runway (years): 0.38y
• Revenue CAGR (3Y): -2.39%
• R&D intensity: 63.63%
• Revenue growth YoY: -11.86% (YoY)
• Return on Assets: -201.89%
• FCF margin: -99.41% (Inv. Mode)
• Cash Burn Deceleration: -119.94% QoQ improvement (Worsening)
• Price / Sales: 0.3x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-13.

Price as of 2026-09-07.